Monopar Appoints Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

summarizeSummary

Monopar Therapeutics has appointed Susan Rodriguez as its new Chief Commercial and Strategy Officer, a newly created role to lead commercial strategy as the company prepares for an NDA submission for its late-stage Wilson disease therapy, ALXN1840.

check_boxKey Events

• New Chief Commercial and Strategy Officer Appointed

  Monopar Therapeutics announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately.

• Strategic Role for Commercialization

  This newly created executive role will focus on leading the company's commercial strategy and building out infrastructure in preparation for the planned New Drug Application (NDA) submission for ALXN1840, its late-stage Wilson disease therapy, in the first half of 2026.

• Highly Experienced Biopharma Executive

  Ms. Rodriguez brings over 30 years of biopharmaceutical leadership, including prior roles as Chief Operating Officer of Avadel Pharmaceuticals (acquired for over $2 billion) and Chief Commercial Officer of Ardelyx, where she successfully launched multiple rare disease therapies.

auto_awesomeAnalysis

This strategic appointment strengthens Monopar's leadership team with a highly experienced commercial executive as the company approaches a critical juncture: the planned NDA submission for ALXN1840 in the first half of 2026. Ms. Rodriguez's extensive background in launching rare disease therapies and building commercial infrastructure, including her recent role at Avadel Pharmaceuticals which was acquired for over $2 billion, signals a serious commitment to successful commercialization and maximizing patient access for ALXN1840. This move is a positive indicator for the company's future revenue potential and its ability to transition from a clinical-stage to a commercial-stage biopharmaceutical enterprise.